Dae Yong Park

Dae Yong Park

Auto-generated profile, based on publicly available information

Dae Yong Park

Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
MMMarah Maayah
Marah Maayah
SGScott Grubman
Scott Grubman
SAStephanie Allen
Stephanie Allen
ZYZachary Ye
Zachary Ye
DPDae Yong Park
Dae Yong Park
JHJiun-Ruey Hu
Jiun-Ruey Hu
Cardiac troponin (Tn) plays a central role in the evaluation of patients with angina presenting with acute coronary syndrome. The advent of high-sensitivity assays has improved the analytic sensitivity and precision of serum Tn measurement, but this advancement has come at the cost of poorer specificity. The role of clinical judgment is of heightened importance because, more so than ever, the interpretation of serum Tn elevation hinges on the careful integration of findings from electrocardiographic, echocardiographic, physical exam, interview, and other imaging and laboratory data to formulate a weighted differential diagnosis. A thorough understanding of the epidemiology, mechanisms, and prognostic implications of Tn elevations in each cardiac and non-cardiac etiology allows the clinician to better distinguish between presentations of myocardial ischemia and myocardial injury—an important discernment to make, as the treatment of acute coronary syndrome is vastly different from the workup and management of myocardial injury and should be directed at the underlying cause.

3 October 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
JHJonathan M. Hanna
Jonathan M. Hanna
SWStephen Y. Wang
Stephen Y. Wang
AKAjar Kochar
Ajar Kochar
DPDae Yong Park
Dae Yong Park
ADAbdulla A. Damluji
Abdulla A. Damluji
MNMichael G Nanna
Michael G Nanna
Background: Complex percutaneous coronary intervention (PCI) is increasingly performed in older adults (age ≥75 years) with stable ischemic heart disease. However, little is known about clinical outcomes. Methods and Results: We derived a cohort of older adults undergoing elective PCI for stable ischemic heart disease across a large health system. We compared 12‐month event‐free survival (freedom from all‐cause death, nonfatal myocardial infarction, stroke, and major bleeding), all‐cause death, target lesion revascularization, and bleeding events for patients receiving complex versus noncomplex PCI and derived risk estimates with Cox regression models. We included 513 patients (mean age, 81±5 years). Patients receiving complex PCI versus noncomplex PCI did not significantly differ across a host of clinical characteristics including cardiovascular disease features, noncardiac comorbidities, guideline‐directed medical therapy use, and frailty. Patients receiving complex PCI versus noncomplex PCI experienced worse event‐free survival (80.4% versus 86.8%), which was not significant in adjusted analyses (hazard ratio [HR], 1.38 [95% CI, 0.88–2.16]). All‐cause death at 1 year for patients undergoing complex PCI was nearly double that seen for patients receiving noncomplex PCI (10.2% versus 5.9%), and the risk was significant in models adjusted for clinical characteristics (HR, 1.97 [95% CI, 1.02–3.79]). Target lesion revascularization risk was lower for patients receiving complex PCI (2.2% versus 3.5%, adjusted HR), but bleeding events were not statistically different between groups (25.3% versus 20.5%; P =0.19). Conclusions: Complex PCI in older adults with stable ischemic heart disease was associated with lower risk of target lesion revascularization but higher all‐cause death compared with noncomplex PCI.

21 June 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
DPDae Yong Park
Dae Yong Park
SASeokyung An
Seokyung An
NJNeeraj Jolly
Neeraj Jolly
SASteve Attanasio
Steve Attanasio
NYNeha Yadav
Neha Yadav
AVAviral Vij
Aviral Vij
Background: Bifurcation lesions account for 20% of all percutaneous coronary interventions and represent a complex subset which are associated with lower procedural success and higher rates of restenosis. The ideal bifurcation technique, however, remains elusive. Methods and Results: Extensive search of the literature was performed to pull data from randomized clinical trials that met predetermined inclusion criteria. Conventional meta‐analysis produced pooled relative risk (RR) and 95% CI of 2‐stent technique versus provisional stent on prespecified outcomes. Both frequentist and Bayesian network meta‐analyses were performed to compare bifurcation techniques. A total of 8318 patients were included from 29 randomized clinical trials. Conventional meta‐analysis showed no significant differences in all‐cause mortality, cardiac death, major adverse cardiac events, myocardial infarction, stent thrombosis, target lesion revascularization, and target vessel revascularization between 2‐stent techniques and provisional stenting. Frequentist network meta‐analysis revealed that double kissing crush was associated with lower cardiac death (RR, 0.57; 95% CI, 0.38–0.84), major adverse cardiac events (RR, 0.50; 95% CI, 0.39–0.64), myocardial infarction (RR, 0.60; 95% CI, 0.39–0.90), stent thrombosis (RR, 0.50; 95% CI, 0.28–0.88), target lesion revascularization, and target vessel revascularization when compared with provisional stenting. Double kissing crush was also superior to other 2‐stent techniques, including T‐stent or T and protrusion, dedicated bifurcation stent, and culotte. Conclusions: Double kissing crush was associated with lower risk of cardiac death, major adverse cardiac events, myocardial infarction, stent thrombosis, target lesion revascularization, and target vessel revascularization compared with provisional stenting and was superior to other 2‐stent techniques. Superiority of 2‐stent strategy over provisional stenting was observed in subgroup meta‐analysis stratified to side branch lesion length ≥10 mm.

9 September 2023 in Current Cardiology Reports
Verified
Journal Article
Closed access
PDF file
JHJiun-Ruey Hu
Jiun-Ruey Hu
DPDae Yong Park
Dae Yong Park
NANikita Agarwal
Nikita Agarwal
MHMatthew Herzig
Matthew Herzig
GOGeorge Ormseth
George Ormseth
SJStephen P. Juraschek
Stephen P. Juraschek

8 March 2022 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
DPDae Yong Park
Dae Yong Park
SASeokyung An
Seokyung An
MMMukunthan Murthi
Mukunthan Murthi
AKajoe kattoor
ajoe kattoor
AKAmandeep Kaur
Amandeep Kaur
AVAviral Vij
Aviral Vij

2 June 2022 in Clinical Cardiology
Verified
Journal Article
Open access
DPDae Yong Park
Dae Yong Park
SASeokyung An
Seokyung An
AKAmandeep Kaur
Amandeep Kaur
SMSaurabh Malhotra
Saurabh Malhotra
AVAviral Vij
Aviral Vij
Background: The coronavirus disease of 2019 (COVID‐19) is a global pandemic with over 266 million cases and 5 million deaths worldwide. Anti‐COVID‐19 vaccinations have had exceptional success in subduing the incidence, prevalence, and disease severity of COVID‐19, but rare cases of myocarditis have been reported after COVID‐19 vaccinations.Hypothesis: Myocarditis occurring after COVID‐19 mRNA vaccinations have distinguishable clinical characteristics. They usually have a favorable prognosis.Methods: We performed a systematic literature search on PUBMED and MEDLINE database from inception to December 5, 2021. Studies were analyzed based on predetermined eligibility criteria.Results: A total of 57 studies containing 275 cases of COVID‐19 vaccine‐associated myocarditis were catalogued. Mean age was 26.7 years and male to female ratio was 14:1. For 86.9% of patients, myocarditis occurred after the second dose. Average time to onset and length of hospitalization were 3.7 and 3.9 days, respectively. Prognosis was largely benign, but there was a 1.1% reported mortality. Chest pain (95.2%), elevation of troponin (100%), and ST elevation on electrocardiography (68.5%) were common. Nonsteroidal anti‐inflammatory drugs (81.4%) were the most used medication, followed by colchicine (33.1%).Conclusions: Patients with COVID‐19 vaccine‐associated myocarditis are usually younger males presenting with chest pain 3–4 days after receiving their second dose of COVID vaccine. Diagnosis is made by exclusion of all other etiologies. Given significant population benefit from COVID‐19 vaccination, physicians should continue to encourage vaccination while remaining vigilant of the very rare occurrence of myocarditis following COVID‐19 vaccination.